Showing 2801-2810 of 5831 results for "".
- New from Coppertone®: Whipped Sunscreenhttps://practicaldermatology.com/news/new-from-coppertone-whipped-sunscreen/2458309/COPPERTONE® is rolling out new Whipped formula sunscreens. The new formulas are available in the CLEARLYSheer® and WaterBABIES® Pure & Simple line. “For my patients, one of the biggest barriers to using everyday su
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- Non-heterosexual Black Male Teens Use Tanning Beds as Much as Caucasian Female Teenshttps://practicaldermatology.com/news/non-heterosexual-black-male-teens-use-tanning-besds-as-much-as-caucasian-female-teens/2458324/The use of indoor tanning among non-heterosexual black male teens is nearly equal to that of heterosexual white females, according to a study in JAMA Dermatology. The data comes from the 2
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour
- National Psoriasis Foundation Awards 2016 Grants and Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-2016-grants-and-fellowships/2458334/The National Psoriasis Foundation (NPF) awarded more than $1.9 million in research funding in 2016, including 23 new projects from around the world. Established and emerging scientists received awards for their innovative work in advancing the research of p
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl